Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00212316 · ClinicalTrials.gov registry record · Phase 2
Safety and Tolerability Study of Phenylbutyrate in Huntington's Disease (PHEND-HD)
A Phase 2 study, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00212316 is a Phase 2 study that has completed, run by University of Rochester. The registered enrollment target is 60 participants.
The verdict
NCT00212316, a Phase 2 study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability and clinical impact of 15-grams daily of sodium phenylbutyrate (phenylbutyrate) in Huntington's disease and to lay the groundwork for possible subsequent trials designed to specifically address its ability to slow or halt the progression of the disease.
Interventions
- DRUG sodium phenylbutyrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2005-08 |
| Est. Completion | 2006-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00212316
The ClinicalTrials.gov registry entry for NCT00212316 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which sodium phenylbutyrate is the first listed.
NCT00212316 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00212316 about?
NCT00212316 is a clinical study titled "Safety and Tolerability Study of Phenylbutyrate in Huntington's Disease (PHEND-HD)". The purpose of this study is to evaluate the safety, tolerability and clinical impact of 15-grams daily of sodium phenylbutyrate (phenylbutyrate) in Huntington's disease and to lay the groundwork for possible subsequent trials designed to specifically address its ability to slow or halt the progress...
What is the current status of trial NCT00212316?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2005-08. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00212316?
The interventions under investigation include: sodium phenylbutyrate (DRUG).
Who is sponsoring clinical trial NCT00212316?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.